Objective： To explore the effect and mechanism of ginsenoside Rg3 （Shenyi Capsule, 参一胶囊） on the postoperative life span of patients with non-small cell lung cancer （NSCLC）. Methods： The prospective, randomiz...Objective： To explore the effect and mechanism of ginsenoside Rg3 （Shenyi Capsule, 参一胶囊） on the postoperative life span of patients with non-small cell lung cancer （NSCLC）. Methods： The prospective, randomized, controlled method was adopted. One hundred and thirty- three patients with NSCLC were randomly assigned to 3 groups： Shenyi Capsule group （43 cases）, combined therapy group （Shenyi Capsule plus chemotherapy, 46 cases）, and chemotherapy group （44 cases）. The survival rates, immune function and the correlation between vascular endothelial growth factor （VEGF） expression and clinical effect were analyzed in the three groups. Results： （1） The 1-year survival rate in the Shenyi group, the combined group and the chemotherapy group was 76.7% （33/43）, 82.6% （38/46）, and 79.5% （35/44）, respectively; the 2-year survival rate was 67.4% （29/43）, 71.7% （33/46）, and 70.5% （31/44）, respectively; and the 3-year survival rate was 46.5% （20/43）, 54.3% （25/46）, and 47.7% （21/44）, respectively. There was no significant difference among the 3 groups （P〉0.05）. （2） NK cells were increased to different degrees and the ratio of CD4/CD8 was normal in the Shenyi Capsule group and the combined group, while the ratio of CD4/CD8 was disproportional in the chemotherapy group. （3） In the chemotherapy group, the 3-year survival rate was lower in patients with positive expression of VEGF than in patients with negative expression （37.0% vs 64.7%, χ^2=17.9, P〈0.01）, but no significant statistical difference was shown in the other two groups （53.6% vs 55.6%, P〉0.05; 44.4% vs 50.0%, P〉0.05）. Conclusion： Shenyi Capsule, especially in combination with chemotherapy, can improve the life span of patients with NSCLC after operation. The mechanism might be correlated with improving the immune function and anti-tumor angiogenesis.展开更多
目的 寻求使处于生长停滞期的人脐静脉内皮细胞 (HUVEC)增殖寿命延长的方法。 方法 将体外转录质粒 pc DNA3- h TERT用 Bam HI酶切使之线性化 ,经 T7RNA聚合酶催化以转录合成 h TERT m RNA。用脂质体法将 h TERT m RNA导入处于生长...目的 寻求使处于生长停滞期的人脐静脉内皮细胞 (HUVEC)增殖寿命延长的方法。 方法 将体外转录质粒 pc DNA3- h TERT用 Bam HI酶切使之线性化 ,经 T7RNA聚合酶催化以转录合成 h TERT m RNA。用脂质体法将 h TERT m RNA导入处于生长停滞期的 HUVEC。检测 h TERT m RNA导入后细胞端粒酶活性表达与细胞生长增殖情况。 结果 导入 h TERT m RNA后 ,细胞有端粒酶活性的暂时表达 ,增殖寿命较单纯用脂质体处理的对照细胞延长了 7代。 结论 h TERT m RNA导入细胞能可控地、瞬时地重建细胞端粒酶活性 ,可望广泛应用于人体细胞增殖寿命延长的尝试。展开更多
文摘Objective： To explore the effect and mechanism of ginsenoside Rg3 （Shenyi Capsule, 参一胶囊） on the postoperative life span of patients with non-small cell lung cancer （NSCLC）. Methods： The prospective, randomized, controlled method was adopted. One hundred and thirty- three patients with NSCLC were randomly assigned to 3 groups： Shenyi Capsule group （43 cases）, combined therapy group （Shenyi Capsule plus chemotherapy, 46 cases）, and chemotherapy group （44 cases）. The survival rates, immune function and the correlation between vascular endothelial growth factor （VEGF） expression and clinical effect were analyzed in the three groups. Results： （1） The 1-year survival rate in the Shenyi group, the combined group and the chemotherapy group was 76.7% （33/43）, 82.6% （38/46）, and 79.5% （35/44）, respectively; the 2-year survival rate was 67.4% （29/43）, 71.7% （33/46）, and 70.5% （31/44）, respectively; and the 3-year survival rate was 46.5% （20/43）, 54.3% （25/46）, and 47.7% （21/44）, respectively. There was no significant difference among the 3 groups （P〉0.05）. （2） NK cells were increased to different degrees and the ratio of CD4/CD8 was normal in the Shenyi Capsule group and the combined group, while the ratio of CD4/CD8 was disproportional in the chemotherapy group. （3） In the chemotherapy group, the 3-year survival rate was lower in patients with positive expression of VEGF than in patients with negative expression （37.0% vs 64.7%, χ^2=17.9, P〈0.01）, but no significant statistical difference was shown in the other two groups （53.6% vs 55.6%, P〉0.05; 44.4% vs 50.0%, P〉0.05）. Conclusion： Shenyi Capsule, especially in combination with chemotherapy, can improve the life span of patients with NSCLC after operation. The mechanism might be correlated with improving the immune function and anti-tumor angiogenesis.
文摘目的 寻求使处于生长停滞期的人脐静脉内皮细胞 (HUVEC)增殖寿命延长的方法。 方法 将体外转录质粒 pc DNA3- h TERT用 Bam HI酶切使之线性化 ,经 T7RNA聚合酶催化以转录合成 h TERT m RNA。用脂质体法将 h TERT m RNA导入处于生长停滞期的 HUVEC。检测 h TERT m RNA导入后细胞端粒酶活性表达与细胞生长增殖情况。 结果 导入 h TERT m RNA后 ,细胞有端粒酶活性的暂时表达 ,增殖寿命较单纯用脂质体处理的对照细胞延长了 7代。 结论 h TERT m RNA导入细胞能可控地、瞬时地重建细胞端粒酶活性 ,可望广泛应用于人体细胞增殖寿命延长的尝试。
